Stay updated with breaking news from Revascularization Device. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Penumbra (NYSE:PEN – Get Rating) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company’s portfolio of products primarily addresses neuro […]
Penumbra (NYSE:PEN – Get Rating) is scheduled to release its earnings data after the market closes on Tuesday, May 3rd. Analysts expect Penumbra to post earnings of $0.07 per share for the quarter. Penumbra has set its FY 2022 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using […]
Penumbra (NYSE:PEN – Get Rating) and Alpha Tau Medical (NASDAQ:DRTS – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership. Insider and Institutional Ownership 79.4% of Penumbra shares are held […]
Penumbra (NYSE:PEN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company’s portfolio of products primarily addresses […]
Equities analysts expect Penumbra, Inc. (NYSE:PEN – Get Rating) to post earnings per share (EPS) of $0.07 for the current quarter, Zacks reports. Three analysts have made estimates for Penumbra’s earnings. The lowest EPS estimate is $0.06 and the highest is $0.08. Penumbra posted earnings per share of $0.27 in the same quarter last year, […]